Related Experiment Video
Updated: Jul 9, 2026

Phage-mediated Delivery of Targeted sRNA Constructs to Knock Down Gene Expression in E. coli
Published on: March 20, 2016
SMT-738: a novel small-molecule inhibitor of bacterial lipoprotein transport targeting Enterobacteriaceae
E B M Breidenstein1, N Khan1, T Duffy1
1Summit Therapeutics, The Works, Unity Campus , Cambridge, United Kingdom.
Abstract:
Carbapenem-resistant Enterobacteriaceae (CREs) are described by the Centers for Disease Control as an urgent threat, and there is a critical need for new therapeutic agents able to treat infections caused by these pathogens. Herein, we describe the microbiological profile, the mechanism f action, and the in vitro safety as well as the pharmacokinetic (PK)/PD profile of SMT-738, a small molecule belonging to a new chemical class. SMT-738 is active against Enterobacterales [including multi-drug-resistant Escherichia coli with 90% of isolates having a minimum inhibitory concentration (MIC90) of 1 µg/mL and Klebsiella pneumoniae 2 µg/mL] and inactive against a broad panel of Gram-negative and Gram-positive pathogens. SMT-738 displays rapid bactericidal activity (2-4 h) and has a low propensity for resistance development (less than ~10-9). Characterization of resistant mutants following exposure to SMT-738 identified mutations within the lipoprotein transport complex (LolCDE), a clinically unexploited and essential bacterial molecular target in Gram-negative bacteria. SMT-738 has a promising in vitro toxicology profile. Furthermore, PK studies demonstrated that when dosed intravenously, SMT-738 maintained exposure levels across infection sites (bloodstream/urinary tract/lung). Proof-of-concept studies across multiple murine in vivo infection models (bloodstream/pneumonia/urinary tract) demonstrated that SMT-738 significantly reduced the bacterial burden compared to baseline and vehicle control. SMT-738 represents a promising novel drug candidate being developed to address clinically challenging serious life-threatening infections caused by highly resistant Enterobacteriaceae including CRE.
Insights
A new drug, SMT-738, shows potent activity against carbapenem-resistant Enterobacteriaceae (CRE). This novel agent targets essential bacterial mechanisms, offering a promising solution for difficult-to-treat infections.
Area of Science:
- Microbiology and Infectious Diseases
- Pharmacology and Drug Development
Background:
- Carbapenem-resistant Enterobacteriaceae (CRE) pose an urgent global health threat, necessitating novel therapeutic strategies.
- Existing treatments are limited, driving the need for new antimicrobial agents effective against multidrug-resistant pathogens.
Purpose of the Study:
- To characterize the microbiological, mechanistic, safety, and pharmacokinetic/pharmacodynamic (PK/PD) profile of SMT-738, a novel small molecule.
- To evaluate SMT-738's efficacy in preclinical models of Gram-negative bacterial infections.
Main Methods:
- Microbiological profiling, including minimum inhibitory concentration (MIC) determination against key Enterobacterales.
- Mechanism of action studies identifying target mutations in the lipoprotein transport complex (LolCDE).
- In vitro toxicology, pharmacokinetic (PK) studies in animal models, and in vivo efficacy testing in murine infection models (bloodstream, pneumonia, urinary tract).
Main Results:
- SMT-738 demonstrated potent in vitro activity against multidrug-resistant Escherichia coli and Klebsiella pneumoniae (MIC90 of 1-2 µg/mL).
- The compound exhibits rapid bactericidal activity, low propensity for resistance development, and targets the essential LolCDE complex.
- In vivo studies showed significant bacterial burden reduction in bloodstream, pneumonia, and urinary tract infection models, with favorable PK and safety profiles.
Conclusions:
- SMT-738 is a promising novel drug candidate with a unique mechanism of action against challenging Gram-negative pathogens.
- Its favorable in vitro and in vivo profiles support further development for treating serious infections caused by carbapenem-resistant Enterobacteriaceae.
More Related Videos
11:59Isolation of Lipoprotein Particles from Chicken Egg Yolk for the Study of Bacterial Pathogen Fatty Acid Incorporation into Membrane Phospholipids
Published on: May 15, 2019
07:37Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening
Published on: May 13, 2020
Related Concept Videos
Formation of Lipopolysaccharides
Gene Regulation in Microbial Communities: Quorum Sensing
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance